Table 3 Time Trade-Off Preference Values
Health State | Main Analysis Population (n = 120) | Alternate Analysis Population (n = 116) | All Participants (n = 125) |
|---|---|---|---|
HS-1 Treatment with chemotherapy | |||
Mean (95% CI) | 0.36 (0.28–0.43) | 0.35 (0.27–0.42) | 0.37 (0.30–0.45) |
Median | 0.50 | 0.50 | 0.50 |
Q1–Q3 | 0–0.60 | 0–0.60 | 0–0.60 |
HS-2 Consolidation | |||
Mean (95% CI) | 0.46 (0.40–0.53) | 0.46 (0.39–0.52) | 0.47 (0.41–0.53) |
Median | 0.50 | 0.50 | 0.50 |
Q1–Q3 | 0.20–0.70 | 0.20–0.70 | 0.20–0.70 |
HS-3 Transplant | |||
Mean (95% CI) | 0.28 (0.20–0.37) | 0.27 (0.18–0.36) | 0.30 (0.22–0.38) |
Median | 0.50 | 0.50 | 0.50 |
Q1–Q3 | 0–0.60 | 0–0.60 | 0–0.60 |
HS-4 GvHD | |||
Mean (95% CI) | 0.43 (0.36–0.50) | 0.42 (0.35–0.50) | 0.44 (0.37–0.51) |
Median | 0.50 | 0.50 | 0.50 |
Q1–Q3 | 0.20–0.70 | 0.20–0.70 | 0.20–0.70 |
HS-5 Remission | |||
Mean (95% CI) | 0.62 (0.57–0.67) | 0.62 (0.57–0.67) | 0.62 (0.57–0.67) |
Median | 0.70 | 0.70 | 0.70 |
Q1–Q3 | 0.50–0.90 | 0.50–0.83 | 0.50–0.90 |
HS-6 Relapse | |||
Mean (95% CI) | 0.10 (0–0.20) | 0.09 (−0.01–0.19) | 0.12 (0.03–0.22) |
Median | 0.10 | 0.10 | 0.10 |
Q1–Q3 | −0.10–0.50 | − 0.10–0.50 | − 0.10–0.50 |
HS-7 Refractory | |||
Mean (95% CI) | −0.11 (− 0.21 to − 0.01) | −0.11 (− 0.22 to − 0.01) | −0.08 (− 0.18–0.02) |
Median | − 0.10 | −0.10 | − 0.10 |
Q1–Q3 | −0.60–0.30 | − 0.63–0.30 | −0.50–0.50 |
HS-8 Functionally cured | |||
Mean (95% CI) | 0.76 (0.72–0.79) | 0.76 (0.72–0.80) | 0.75 (0.71–0.79) |
Median | 0.80 | 0.80 | 0.80 |
Q1–Q3 | 0.70–0.90 | 0.70–0.90 | 0.70–0.90 |